Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Renexxion Ireland, a Gastrointestinal Biotech Company Announces $100M Investment Commitment

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, announced today that it has entered into a share subscription agreement with GEM Global Yield LLC SCS (“GEM”), a Luxembourg-based private equity group for an investment of up to $100 Million to be made within 36 months after a public listing.

In this tailored agreement, Renexxion Ireland will control the amount and timing of any drawdowns under this facility with no minimum subscription obligation and will issue shares of common stock. The proceeds from this capital investment will further the company’s lead program, naronapride and advance additional new programs.

“The benefits of a funding commitment from a strong institutional investor like GEM are certainty and faster access to capital as a publicly listed company, critical elements for rapid growth,” said Peter Milner M.D., FACC, Chairman and CEO.

Renexxion Ireland’s lead program is naronapride, a late-stage potential best-in-class drug candidate for unmet GI indications in the upper and lower GI tract.  In scientific studies naronapride has been demonstrated to possess a unique combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties, both clinically validated targets.  Naronapride is designed to be minimally absorbable, is locally active in gut lumen, and in clinical studies its side-effect profile is indistinguishable from placebo. Four positive Phase-II studies have been completed and naronapride is Phase-III ready in chronic idiopathic constipation (CIC) and gastro-esophageal reflux disease (GERD). Renexxion Ireland is currently advancing an additional research program in inflammatory bowel disease (“IBD”).

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine